A phase III multi-center, double-blind, placebo-controlled, parallel group 24-week study to assess the efficacy and safety of two dose regimens of liquid certolizumab pegol [Cimzia] as additional medication to methotrexate in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Certolizumab pegol (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RAPID-2
- Sponsors UCB
- 04 Jun 2020 According to an UCB media release, post-hoc analysis results from the pooled studies RAPID 1 (NCT00152386), RAPID 2 (NCT00175877), J-RAPID (NCT00791999) and RAPID-C (NCT02151851) were presented at the Annual European Congress of Rheumatology (EULAR) 2020.
- 10 May 2011 Results from a post hoc analysis of this trial (RAPID-2) have been published in the Annals of Rheumatic Diseases according to a UCB media release; results were also reported in the media release.
- 17 Mar 2011 Secondary endpoint results published in the Annals of the Rheumatic Diseases.